TREAT study

A multi-centre, parallel arm, randomised, open label, controlled, non-inferiority trial of mepolizumab and omalizumab with a run-in to identify Severe Therapy Resistant Asthma (STRA) and Refractory Difficult Asthma.

The trial aims to recruit 500 children with severe asthma aged six to sixteen years into the initial Run-in phase and 150 participants to proceed into the randomised phase which lasts for 52 weeks. Recruited eligible participants will be randomised (1:1) to either omalizumab or mepolizumab